Compare AMPH & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPH | PHAR |
|---|---|---|
| Founded | 1996 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2014 | N/A |
| Metric | AMPH | PHAR |
|---|---|---|
| Price | $29.26 | $16.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $31.00 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 330.6K | 36.6K |
| Earning Date | 02-26-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.27 | 0.00 |
| Revenue | ★ $723,305,000.00 | $362,274,000.00 |
| Revenue This Year | $1.37 | $25.19 |
| Revenue Next Year | $4.84 | $4.47 |
| P/E Ratio | ★ $12.62 | $2,960.75 |
| Revenue Growth | N/A | ★ 26.78 |
| 52 Week Low | $20.39 | $7.50 |
| 52 Week High | $33.42 | $21.34 |
| Indicator | AMPH | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 66.12 | 39.57 |
| Support Level | $28.45 | $15.95 |
| Resistance Level | $29.37 | $18.03 |
| Average True Range (ATR) | 0.86 | 0.76 |
| MACD | 0.28 | -0.49 |
| Stochastic Oscillator | 93.33 | 7.05 |
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.